Published in Cancer Weekly, November 1st, 2005
Ritchie Capital led the round which included existing investors Intersouth Partners, Lilly Ventures, Mediphase Venture Partners, Takeda Research Investment and Seaflower Ventures.
Serenex also announced that it has in-licensed worldwide rights to develop and commercialize SNX-1012 for chemotherapy and radiation-induced oral mucositis from Mucosal Therapeutics, LLC. Oral mucositis is one of the most debilitating adverse events related to cancer treatment, yet options for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.